Events & Ideas
Upcoming Events
Our Work
Prescription Medicines, Dietary Ingredients & Supplements
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines
Belouin SJ, Averill LA, Henningfield JE, Xenakis SN, Donato I, Grob CS, Berger A, Magar V, Danforth AL, Anderson BT. Neuropharmacology. 2022 Nov 15;219:109214. View publication
Prescription Medicines, Dietary Ingredients & Supplements
Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care
Ross S, Agrawal M, Griffiths RR, Grob C, Berger A, Henningfield JE. Neuropharmacology. 2022 Sep 15;216:109174. View publication
Prescription Medicines, Dietary Ingredients & Supplements
Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective
Henningfield JE, Ashworth J, Heal DJ, Smith SL. J Psychopharmacol. 2023 Jan 1:2698811221140004. View publication
Prescription Medicines, Dietary Ingredients & Supplements
Respiratory effects of oral mitragynine and oxycodone in a rodent model
Henningfield JE, Rodricks JV, Magnuson AM, Huestis MA. Psychopharmacology (Berl). 2022 Dec;239(12):3793-3804. View publication
Dietary Ingredients & Supplements
Kratom policy: The challenge of balancing therapeutic potential with public safety
Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D. The International Journal on Drug Policy 70:70–77, 2019 View publication